India, July 23 -- Clinuvel Pharmaceuticals Limited (CUV.AX), a pharmaceutical company, on Thursday announced a strategic reorganisation within the company effective from January 1, 2027, that includes a relocation of headquarters to the U.S., and significant cuts to the workforce.
Currently located primarily in Australia, the company has established a portfolio of melanocortin peptides advancing photomedicine and vitiligo. The company markets SCENESSE, approved in the U.S., Europe, Canada, Israel and Australia as a systemic photoprotective drug for the prevention of phototoxicity in patients with erythropoietic protoporphyria (EPP).
The company stated that its corporate headquarters would be relocated to the U.S. on the aforementioned dat...